OC9 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet materially lower leverage gives Omnicell greater financial flexibility to fund product development, customer deployments, and strategic initiatives. A sizable equity base also improves resilience if hospital capital spending slows, while reducing balance-sheet risk over the next several quarters.
Positive Cash GenerationConsistently positive and improving free cash flow provides internal funding for innovation, implementation capacity, and customer financing programs without relying heavily on external capital. This strengthens business durability and helps offset volatility in quarterly revenue or bookings.
Pipeline And Product ExpansionA larger pipeline, new competitive wins, and a developing product roadmap support Omnicell’s ability to expand within hospitals and health systems. Titan XT and OmniSphere could deepen the installed-base relationship and create additional platform-driven enterprise opportunities.
Bears Say
Thin ProfitabilityThin net margins leave limited room for execution errors, cost inflation, or weaker utilization to reduce earnings. The history of losses and low profits also indicates that improved revenue and EBITDA have not yet translated into consistently strong bottom-line returns.
Bookings Timing RiskA wide bookings range and lengthy customer capital-approval cycles make revenue conversion less predictable over the next several quarters. Delayed large deployments could defer product revenue, disrupt operating leverage, and make growth dependent on the timing of a few major decisions.
Slower Recurring-Revenue RampSlower consumables adoption can delay expansion of recurring revenue and reduce the pace at which Omnicell monetizes its installed base. If the ramp remains delayed, subscription and usage-linked growth may provide less near-term support for revenue mix and margin improvement.
Omnicell News
OC9 FAQ
What was Omnicell’s price range in the past 12 months?
Currently, no data Available
What is Omnicell’s market cap?
Omnicell’s market cap is CHF1.21B.
When is Omnicell’s upcoming earnings report date?
Omnicell’s upcoming earnings report date is Nov 04, 2026 which is in 42 days.
How were Omnicell’s earnings last quarter?
Omnicell released its earnings results on Jul 30, 2026. The company reported CHF0.765 earnings per share for the quarter, beating the consensus estimate of CHF0.381 by CHF0.384.
Is Omnicell overvalued?
According to Wall Street analysts Omnicell’s price is currently Undervalued.
Does Omnicell pay dividends?
Omnicell does not currently pay dividends.
What is Omnicell’s EPS estimate?
Omnicell’s EPS estimate is 0.34.
How many shares outstanding does Omnicell have?
Currently, no data Available
What happened to Omnicell’s price movement after its last earnings report?
Omnicell reported an EPS of CHF0.765 in its last earnings report, beating expectations of CHF0.381. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Omnicell?
Currently, no hedge funds are holding shares in CH:OC9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Omnicell Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF45.24 (― Upside)
CHF45.24 (― Upside)
Blogger Sentiment
Bullish
CH:OC9 Sentiment 67%
Sector Average 63%
Sector Average 63%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.47%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.83%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Omnicell
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
OC9 Company Deck
OC9 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents solid operating and financial execution in Q2 — revenue at the high end of guidance, strong cash generation, several strategic product wins and a materially larger pipeline — coupled with raised full-year profitability targets. However, key near-term risks include timing uncertainty around large product bookings (broad bookings range), a one-time tariff refund that boosted Q2 results, memory chip cost pressures (~$6M impact, ~50–80 bps margin effect), and slower consumables/ARR timing. Overall, the tone balances strong execution and long-term opportunity against near-term timing and supply-chain headwinds.View all CH:OC9 earnings summaries